Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Orphan Drugs Market 2021
25 June 2021
An orphan drug is a medicine for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition that is rare or where the medicine is unlikely to generate sufficient profit to justify research and development costs. They are orphans because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions. The global orphan drugs market is set to grow by US$ 69 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 5.5% during the forecast period, according to data and analytics company StrategyHelix. Availability of exclusivity for orphan drugs, rising prevalence of rare diseases, favorable government policies are expected to boost the market growth in the coming years.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for orphan drugs. The global orphan drugs market is segmented on the basis of drug type, top selling drug, disease type, and region. By drug type, it is categorized into biological drugs, and non-biological drugs. The biological drugs segment held the largest market share in 2020. By top selling drug, the orphan drugs market is divided into Revlimid, Tafinlar, Hemlibra, Darzalex, Kyprolis, Myozyme, Vyndaqel, Soliris, Ninlaro, Imbruvica, and others. The Revlimid segment accounted for the largest market share in 2020. Based on disease type, the orphan drugs market is divided into oncology, blood disorders, central nervous system, respiratory system, immunomodulators, cardiovascular therapies, and others.
The report has profiled some of the key players of the market such as AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., BioMarin Pharmaceutical Inc., Bristol-Myers Squibb Company, Celgene Corporation, CSL Behring GmbH, Eisai Co. Ltd., F. Hoffmann-La Roche AG, Incyte Corporation, Jiangsu Hengrui Medicine Co. Ltd., Johnson & Johnson, Novartis AG, Pfizer Inc., Sanofi S.A., Syros Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Vertex Pharmaceuticals Inc..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the orphan drugs market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Drug type: biological drugs, and non-biological drugs
Top selling drug: Revlimid, Tafinlar, Hemlibra, Darzalex, Kyprolis, Myozyme, Vyndaqel, Soliris, Ninlaro, Imbruvica, and others
Disease type: oncology, blood disorders, central nervous system, respiratory system, immunomodulators, cardiovascular therapies, and others
Region: North America, Asia Pacific, Europe, and Rest of the World (ROW)
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the global orphan drugs market
Identify regional strategies and strategic priorities on the basis of local data and analysis
Pinpoint growth sectors and trends for investment
Understand what the future of the global orphan drugs market looks like
Identify the competitive landscape and window of opportunity
Table of Contents
1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Orphan Drugs Market by Drug Type
4.1 Biological Drugs
4.2 Non-Biological Drugs
5. Orphan Drugs Market by Top Selling Drug
6. Orphan Drugs Market by Disease Type
6.2 Blood Disorders
6.3 Central Nervous System
6.4 Respiratory System
6.6 Cardiovascular Therapies
7. Orphan Drugs Market by Region
7.1 North America
7.2 Asia Pacific
7.4 Rest Of The World (Row)
8. Company Profiles
8.1 AbbVie Inc.
8.2 Alexion Pharmaceuticals Inc.
8.3 Amgen Inc.
8.4 AstraZeneca plc
8.5 Biogen Inc.
8.6 BioMarin Pharmaceutical Inc.
8.7 Bristol-Myers Squibb Company
8.8 Celgene Corporation
8.9 CSL Behring GmbH
8.10 Eisai Co., Ltd.
8.11 F. Hoffmann-La Roche AG
8.12 Incyte Corporation
8.13 Jiangsu Hengrui Medicine Co., Ltd.
8.14 Johnson & Johnson
8.15 Novartis AG
8.16 Pfizer Inc.
8.17 Sanofi S.A.
8.18 Syros Pharmaceuticals, Inc.
8.19 Takeda Pharmaceutical Co. Ltd.
8.20 Vertex Pharmaceuticals, Inc.
9.1 About StrategyHelix